Alvotech (NASDAQ: ALVO) reports FDA Form 483 but maintains 2026 BLA approval outlook

Rhea-AI Filing Summary

Alvotech reports that the U.S. FDA has completed a routine cGMP surveillance inspection of its Reykjavik, Iceland manufacturing facility, which ended on May 8, 2026 with the issuance of a Form 483. The company believes the observations can be addressed quickly and do not raise substantial issues with the site or its operations.

Alvotech states it is well positioned to resubmit the relevant Biologics License Applications during the current quarter, after final data are compiled, and continues to expect FDA approval for these BLAs during 2026. The company highlights that the inspection outcome supports the strength of cGMP fundamentals and recent site improvements.

Insights

Biopharma regulatory analyst

Routine FDA inspection yields Form 483, but Alvotech keeps 2026 BLA approval timeline.

The FDA completed a routine cGMP surveillance inspection at Alvotech’s Reykjavik facility, issuing a Form 483 on May 8, 2026. The company characterizes the observations as addressable and not indicative of substantial issues with the site or operations.

Importantly for a biosimilar-focused company, Alvotech says it remains on track to resubmit the relevant Biologics License Applications this quarter and still expects FDA approval during 2026. The company also links the inspection outcome to strengthened cGMP fundamentals and recent improvements at the facility.

For investors in regulated biotech manufacturing, the key dependency is successful remediation of the Form 483 observations and timely BLA resubmissions. Subsequent regulatory updates and approvals during 2026 will clarify how this inspection ultimately affects product launch timing.

Key Figures

Inspection completion date: May 8, 2026 Form type issued: Form 483 Expected BLA approvals: 2026 +3 more

6 metrics

Inspection completion date May 8, 2026 End of FDA cGMP surveillance inspection at Reykjavik facility

Form type issued Form 483 Issued by FDA at conclusion of Reykjavik inspection

Expected BLA approvals 2026 Company expectation for FDA approval of relevant BLAs

BLA resubmission timing Current quarter Alvotech expects to resubmit relevant BLAs this quarter

Marketed biosimilars 5 products Approved and marketed in multiple global markets

Pipeline biosimilars 9 candidates Disclosed biosimilar candidates in development

Key Terms

Form 483, cGMP surveillance inspection, Biologics License Applications, biosimilar medicines, +1 more

5 terms

Form 483 regulatory

"At the conclusion of the inspection on May 8, 2026, the FDA issued a Form 483."

Form 483 is a written list of inspectional observations issued by the U.S. Food and Drug Administration when inspectors spot potential problems during a facility visit, such as gaps in manufacturing, recordkeeping, or safety controls. For investors it matters because receiving a Form 483 signals possible regulatory trouble that can lead to remediation costs, production delays, product holds or fines—similar to a visible warning sign that a company must fix operations to stay compliant.

cGMP surveillance inspection regulatory

"the FDA has completed a routine cGMP surveillance inspection of the company’s manufacturing facility"

Biologics License Applications regulatory

"well positioned to resubmit the relevant Biologics License Applications this quarter"

A biologics license application is a formal request submitted to a regulatory agency to get permission to market a biological medicine—such as vaccines, blood products, or gene and cell therapies—after clinical testing. It’s like applying for a safety and quality permit that lets a company sell a complex medical product; investors watch its progress because approval clears the way for revenue while rejection or delays create significant financial risk.

biosimilar medicines financial

"specializing in the development and manufacture of biosimilar medicines for patients worldwide"

Biosimilar medicines are follow‑on versions of complex biological drugs made from living cells that are highly similar to an original approved biologic but not exact copies, like a near‑identical twin rather than a factory‑made duplicate. They matter to investors because they increase competition and typically lower prices for high‑cost therapies, which can reduce revenue for original drugmakers while creating new market opportunities for companies that develop and sell biosimilars.

forward-looking statements regulatory

"Certain statements in this communication may be considered “forward-looking statements”"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-41421

Alvotech
(Translation of registrant's name into English)

9, Rue de Bitbourg,
L-1273 Luxembourg,
Grand Duchy of Luxembourg
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Incorporation by Reference 

This Report on Form 6-K (this “Report”) of Alvotech (the “Company”) excluding Exhibit 99.1 attached hereto, shall be deemed to be incorporated by reference into the Company’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), the Company’s registration statement on Form F-3ASR (File No. 333-289006), and the Company’s registration statement on Form S-8 (File No. 333-266881) and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit 99.1 to this Report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. 

Press Releases 

On May 11, 2026, Alvotech issued a Press Release announcing that the U.S. Food and Drug Administration (FDA) had completed a routine cGMP surveillance inspection of the company’s manufacturing facility in Reykjavik, Iceland, concluding with the issuance of a Form 483. A copy of the Press Release is furnished herewith as exhibit 99.1.

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated May 11, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Alvotech
		(Registrant)
Date: May 11, 2026		/s/ Tanya Zharov
		Tanya Zharov
		General Counsel

EXHIBIT 99.1

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

- Company remains on track for BLA resubmissions in the second quarter

REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announces that the U.S. Food and Drug Administration (FDA) has completed a routine cGMP surveillance inspection of the company’s manufacturing facility in Reykjavik, Iceland.

At the conclusion of the inspection on May 8, 2026, the FDA issued a Form 483. The company believes the observations can be addressed quickly and do not raise any substantial issues with the site or its operations.

Based on the outcome of the inspection, Alvotech is well positioned to resubmit the relevant Biologics License Applications this quarter, once the final data have been compiled.

More importantly, the company believes the outcome of this inspection demonstrates the strong cGMP fundamentals of the site and the robustness of all the improvements the company has implemented since last year.

Alvotech continues to expect FDA approval for the relevant BLAs during 2026.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

Alvotech Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

FAQ

What did the FDA inspection at Alvotech (ALVO) Reykjavik facility conclude?

The FDA completed a routine cGMP surveillance inspection of Alvotech’s Reykjavik facility and issued a Form 483 on May 8, 2026. Alvotech believes the observations are manageable and do not indicate substantial issues with the site or its operations.

How does the FDA Form 483 affect Alvotech (ALVO) BLA timelines?

Alvotech states it remains well positioned to resubmit the relevant Biologics License Applications this quarter. The company continues to expect FDA approval for these BLAs during 2026, indicating it does not foresee major timeline changes from the Form 483.

What type of inspection did the FDA perform at Alvotech (ALVO)?

The FDA conducted a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland. Surveillance inspections periodically assess ongoing compliance with cGMP standards at pharmaceutical and biotechnology manufacturing sites.

How many biosimilars does Alvotech (ALVO) currently market globally?

Alvotech reports that five biosimilars are already approved and marketed in multiple global markets. These include biosimilars to Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva, supporting a diversified commercial biosimilar portfolio alongside its development pipeline.

What is in Alvotech (ALVO) current biosimilar development pipeline?

Alvotech discloses nine biosimilar candidates in development targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. This pipeline complements its already marketed biosimilars and is supported by strategic commercial partnerships across major global regions.

What future regulatory milestones does Alvotech (ALVO) expect in 2026?

Alvotech continues to expect FDA approval for the relevant Biologics License Applications during 2026. This expectation follows completion of the FDA’s surveillance inspection and planned BLA resubmissions, and would be a key step toward expanding its U.S. biosimilar offerings.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.9 KB